You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Platinum analogue

Showing 1 - 25 of 3,295
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC (NSCLC) Trial (Sotorasib, Pembrolizumab)

Not yet recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • (no location specified)
Jun 26, 2023

Head and Neck Squamous Cell Carcinoma Trial in Worldwide (Magrolimab, Pembrolizumab, Docetaxel)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Chandler, Arizona
  • +59 more
Jan 20, 2023

Cervical Cancer Trial in Chongqing, Fuzhou (TQB2868 injection, Paclitaxel injection, Cisplatin injection)

Not yet recruiting
  • Cervical Cancer
  • TQB2868 injection
  • +4 more
  • Chongqing, Chongqing, China
  • +1 more
Aug 17, 2023

NSCLC (NSCLC) Trial (Ociperlimab, Placebo, Tislelizumab)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • (no location specified)
Mar 17, 2023

NSCLC Trial in Japan, Korea, Republic of, Singapore (capmatinib, pemetrexed, cisplatin)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • Kashiwa, Chiba, Japan
  • +3 more
Jan 31, 2023

Small-cell Lung Cancer Trial in Worldwide (Berzosertib, Topotecan)

Active, not recruiting
  • Small-cell Lung Cancer
  • Santa Rosa, California
  • +47 more
Jun 24, 2022

Non Small Cell Lung Cancer, Brain Metastases, Adult, Lung Cancer Trial in Spain (Ipilimumab, Nivolumab, Carboplatin)

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Badalona, Barcelona, Spain
  • +17 more
Jun 1, 2022

Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients Trial in Dhaka (lidocaine transdermal patch)

Recruiting
  • Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients
  • lidocaine transdermal patch
  • Dhaka, Bangladesh
    Bangabandhu Sheikh Mujib Medical University
May 22, 2023

A Real-World Patient-Reported Outcomes Study in Long-Term Use of

Recruiting
  • Ovarian Cancer
    • Beijing, Beijing, China
      Peking Union Medical College Hospital
    Sep 13, 2023

    Recurrent Ovarian Carcinoma Trial in Worldwide (Placebo, Carboplatin, Paclitaxel)

    Active, not recruiting
    • Recurrent Ovarian Carcinoma
    • Placebo
    • +6 more
    • Charleroi, Belgium
    • +70 more
    Feb 7, 2022

    NSCLC (NSCLC) Trial in Worldwide (Tislelizumab, Docetaxel, Sitravatinib)

    Recruiting
    • Non-Small Cell Lung Cancer (NSCLC)
    • Tucson, Arizona
    • +112 more
    Nov 9, 2022

    Ovarian Cancer, Relapsed Ovarian Cancer, Fallopian Tube Cancer Trial (Carboplatin)

    Not yet recruiting
    • Ovarian Cancer
    • +6 more
    • (no location specified)
    Oct 27, 2022

    Chemo-induced Peripheral Neuropathy, Pediatric Cancer Trial in Basel (Playful sensorimotor training)

    Recruiting
    • Chemotherapy-induced Peripheral Neuropathy
    • Pediatric Cancer
    • Playful sensorimotor training
    • Basel, Switzerland
    • +1 more
    Nov 3, 2022

    HER2-negative Breast Cancer, Triple Negative Breast Cancer Trial in France, Germany, Ireland (Capecitabine, Carboplatin,

    Recruiting
    • HER2-negative Breast Cancer
    • Triple Negative Breast Cancer
    • Brasschaat, Belgium
    • +161 more
    Nov 2, 2022

    Advanced Breast Cancer Trial in Beijing (The combination of Dalpiciclib with physician-selected endocrine therapy, Chemotherapy

    Recruiting
    • Advanced Breast Cancer
    • The combination of Dalpiciclib with physician-selected endocrine therapy
    • Chemotherapy selected by the physician
    • Beijing, Beijing, China
      Peking Union Medical College Hospital
    May 22, 2023

    Collect Real-world Clinical and Patient-reported Outcomes in

    Recruiting
    • Ovarian Cancer
      • Aachen, Germany
      • +64 more
      Jul 29, 2022

      NSCLC Trial (fianlimab, cemiplimab, Pemetrexed)

      Not yet recruiting
      • Non-small Cell Lung Cancer
      • (no location specified)
      Mar 23, 2023

      Platinum-resistant Ovarian Cancer

      Not yet recruiting
      • Ovarian Cancer
      • pegylated liposomal doxorubicin
      • (no location specified)
      Aug 2, 2023

      Triple Negative Breast Cancer Trial in Dhaka (Doxorubicin, Cyclophosphamide, Paclitaxel)

      Not yet recruiting
      • Triple Negative Breast Cancer
      • Dhaka, Bangladesh
        Bangabandhu Sheikh Mujib Medical University
      May 24, 2023

      Small Cell Lung Cancer (SCLC) Trial (Tarlatamab, Lurbinectedin, Topotecan)

      Not yet recruiting
      • Small Cell Lung Cancer (SCLC)
      • (no location specified)
      Feb 21, 2023

      Ovarian Cancer Trial (Aribulin;carboplatin;bevacizumab)

      Not yet recruiting
      • Ovarian Cancer
      • (no location specified)
      Jul 20, 2023

      Cervical Cancer Trial in Wuhan (Recombinant humanized anti-PD-1 mAb injection, Cisplatin, Bevacizumab Injection)

      Not yet recruiting
      • Cervical Cancer
      • Recombinant humanized anti-PD-1 monoclonal antibody injection
      • +4 more
      • Wuhan, Hubei, China
        Tongji Hospital affiliated to Tongji Medical College of Huazhong
      Nov 3, 2023

      Small Cell Lung Carcinoma Trial in Worldwide (Pembrolizumab/Vibostolimab Co-Formulation, Saline , Etoposide)

      Recruiting
      • Small Cell Lung Carcinoma
      • Pembrolizumab/Vibostolimab Co-Formulation
      • +5 more
      • Los Angeles, California
      • +122 more
      Jan 27, 2023

      GSTP1 and Other Gene Polymorphisms With Platinum-induced

      Not yet recruiting
      • Non-small Cell Lung Cancer
      • GSTP1 A313G （AA）
      • (no location specified)
      Nov 16, 2023

      NSCLC Trial in Tianjing (Envalfolimab subcutaneously injected+Platinum-based doublet chemo intravenous injection,

      Not yet recruiting
      • Non-small Cell Lung Cancer
      • Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection
      • placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection
      • Tianjing, Tianjin, China
        Tianjin cancer hospital
      Nov 3, 2023